Blog

The MOF closed marginally higher in May. Read more.

Equities returned to winning ways in May following a negative month. Read more.

The equity market stumbled in April with the S&P 500 decreasing by 4.1%, breaking its streak of five consecutive positive months. Read more.

Are they, aren’t they, they are, they aren’t – Interest Rates. Read more.

The Merchant Biotech Fund retreated a little this month finishing the month at $1.3940. Read more.

The MOF continued to recover through the month of March. Read more.

The MOF rebounded slightly in February. Read more.

The month of February was a strong month for the Merchant Biotech Fund (Fund or MBF) finishing up 16.71%. Read more.  

We are starting to see green shoots in our sector of the market of late. Read more.

The Merchant Biotech Fund (MBF or Fund) started the 2024 calendar year well, finishing up 11.12% for the month of January. Read more.

Closing out the year the Merchant Biotech Fund finished up strongly. Read more.

Pleasingly the Merchant Opportunities Fund rebounded somewhat during the month of December. Read more.

The Merchant Biotech Fund (MBF or Fund) had a strong month in November, finishing at $1.0058. Read more.

The bright spot at Merchant has been the performance of the Merchant Biotech Fund. Read more.

The general market softened into September and the biotech sector held its ground. Read more.

Greetings from Munich. I am here at the moment assisting HAPA (EuroCann). Read more.

At the end of July, it appeared the Australian inflation rate was softening with monthly CPI hitting a 16-month low. Read more.

A quiet month in the markets post June 30th selling in Small-Cap land. Read more.

The Merchant Opportunities Fund softened in the month of June. Read more.

The Merchant Biotech Fund finished up 43.25% for the financial year. Read more.

The Merchant Biotech Fund (“MBF” or “the Fund”) is up 59% for the financial year vs the ASX Healthcare 300 Index (XHK) up 6.09% over the same period. Read more.

The overall market was relatively stagnant during the month of April. Read more.

The Merchant Biotech Fund closed up 5.5% for the month. Read more.

March was a tale of two halves – first half being terrible and second half being less terrible… Read more.

Global equities declined in February after a strong January. Merchant Biotech Fund (MBF or Fund) retreated a little to finish the month $0.7691.Read more.

The month of February was a tale of two halves – first half of the month being relatively good and second half being relatively bad as the index wobbled across the board as a result of continued increases in global interest rates. Read more.

A solid January could be a good sign for the market and potentially foreshadow a continued uptick in the months that follow. Read more.

Another relatively benign month for the Merchant Opportunities Fund. Read more.

The Merchant Opportunities Fund (MOF) is currently up 19.60% net of fees since 30 June 2022. Read more.

The Merchant Biotech Fund (MBF) finished December up 29.34% for the Financial Year. Read more.

November started on a sombre note amid the Fed’s rate hike and better-than-expected job numbers. Read more.

The ASX continued to tread water in November and settled into the Christmas trading period with a marked drop in liquidity despite an overall bullish trend. Read more.

Global equity markets rounded the month out higher after a brutal September slump. In the US the Dow ended October with a gain of +13.96%, its best monthly advance since January 1976 and its 10th best month of the last century. Read more.

Apologies for the lateness of this newsletter, I’ve just returned from Frankfurt where we’ve been visiting HAPA Pharm, our German Medical Cannabis holding as it readies to list in the new year. Read more.

This month the bear market intensified, with the S&P 500 joining the Dow Jones in undercutting their June lows and the Nasdaq composite sitting just above that level. Read more.

The Merchant Opportunities Fund (MOF) had a relatively benign month given the global market swings during September. Read more.

The question we wanted answered in July was “can the rally last?”  August provided the answer. Read more.

The Merchant Opportunities Fund (MOF or Fund) pulled back slightly along with the market during the month of August to be up 18.40% for the Financial Year. Read more.

At the closing bell on the last trading day of the Financial Year, the ASX Biotech Sector was down approximately 40% for the full Financial Year. Read more.

Well, that was a financial year to forget! Read more.

The MOF is currently down 15.41% since 30 June against a Small Ordinaries Index that is at the time of writing, down 19.94% for the Financial Year. Read more.

Against the ASX & US Listed Biotech Indexes we are faring better but at the moment it’s all a little painful. Read more.

April brought another volatile month on the stock market. The release of inflation numbers and a rise in interest rates both globally and domestically led to a shakeout. Read more.

With the Small Ordinaries off 15.36% for the 6 months, the Merchant Opportunities Fund (MOF) over for the financial year is currently down 12.18%. Read more.

As the dust settles on the month of March 2022 for the Merchant Biotech Fund increasing inflation and the Russian war in Ukraine continue to plague the technology/healthcare sector. Read more.

I’m helping OzHarvest raise money to feed people in need and I’d love your support. Read more.

The Merchant Opportunities Fund is currently down 6.25% for the Financial Year having regained some ground to March 31st. Read more.

Biotech companies are at the centre of future success, with one investment group setting its sights on the industry. These are the companies working to help us live longer, healthier lives by creating cutting edge treatments for devastating diseases. Merchant Funds’ new Biotech fund focuses on emerging Australian biotech, medical and health sciences companies, giving […]

The Merchant Biotech Fund continued to suffer during February with the Biotechnology and Technology sectors both being hardest hit as a result of the Russian invasion of Ukraine.

The Merchant Opportunities Fund continued its retracement at the hands of the market gods in February.